(Q37070946)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Novel insights in the treatment of diabetic nephropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

B F Schrijvers

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

278-290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18229460%20AND%20SRC:MED&resulttype=core&format=json

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Reversal of lesions of diabetic nephropathy after pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Diabetes and advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

The structural organization of the human Na+/myo-inositol cotransporter (SLC5A3) gene and characterization of the promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Combination ACEI and ARB therapy: additional benefit in renoprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Lack of effect of captopril on glomerular hyperfiltration in normoalbuminuric normotensive insulin-dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Paradoxes of nitric oxide in the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Smoking is associated with progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes--data from the National Diabetes Register in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Smoking, oxidative stress and inflammation: impact on resting energy expenditure in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Controlled low protein diets in chronic renal insufficiency: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

The insulin-like growth factor-binding protein (IGFBP) superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Acute effects of a somatostatin analogue on kidney function in type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Mechanism of activation of the TGF-beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Over-expression of platelet-derived growth factor in human diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Activation of transforming growth factor-β1 in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.043